Persistent immune thrombocytopaenic purpura associated with SARS‐CoV‐2 infection – Wiley

We describe evolution of persistent immune thrombocytopaenic purpura (ITP) from acute ITP in a young woman with clinically otherwise inapparent severe acute respiratory syndrome coronavirus 2 (SARSCoV2) infection (COVID19); her development of ITP was matter for an earlier report.[1] ITP is an acquired disease in which thrombocytopaenia results from autoantibodies against platelet antigens. Approximately 10% of patients with acute ITP develop persistent (lasting 312 months) or chronic (>12 months)…

Click here to view the original article.